
BRIM — Investor Relations & Filings
BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45772690 | 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | ||
| 45772689 | 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | ||
| 45772688 | 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | ||
| 45772687 | 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | ||
| 45772686 | 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | ||
| 45772685 | 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese | ||
| 45746302 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45746232 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741513 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741321 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 45544696 | 115年第1季財務報告書 — 202601_6885_AI1.pdf | 2026-05-11 | Chinese | ||
| 33964967 | 115年4月變更登記 | 2026-04-10 | Chinese | ||
| 33964970 | 公司基本資料 | 2026-04-10 | Chinese | ||
| 33902475 | 公告本公司限制員工權利新股收回註銷完成變更登記 | 2026-04-09 | Chinese | ||
| 33893046 | 115年04月僑外投資持股 | 2026-04-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Predict S.p.A.
Develops and distributes AI medical solutions for imaging, …
|
PRE | IT | Professional, scientific and te… |
|
PRESCIENT THERAPEUTICS LIMITED
Clinical-stage oncology firm developing modular cell therap…
|
PTX | AU | Professional, scientific and te… |
|
PreveCeutical Medical
Health sciences company researching and developing innovati…
|
PREV | CA | Professional, scientific and te… |
|
ProMIS Neurosciences Inc.
Develops selective antibody therapeutics for neurodegenerat…
|
PMN | CA | Professional, scientific and te… |
|
Propanc Biopharma, Inc.
Clinical-stage company developing cancer treatments to prev…
|
PPCB | US | Professional, scientific and te… |
|
ProQR Therapeutics N.V.
Develops RNA therapies for severe genetic disorders using i…
|
PRQR | NL | Professional, scientific and te… |
|
Prostatype Genomics AB
Develops a genetic test that assesses prostate cancer aggre…
|
PROGEN | SE | Professional, scientific and te… |
|
Protagenic Therapeutics, Inc.\new
Develops peptide-based therapeutics for stress-related neur…
|
PTIX | US | Professional, scientific and te… |
|
Protara Therapeutics, Inc.
Clinical-stage biopharma developing therapies for cancer an…
|
TARA | US | Professional, scientific and te… |
|
PROTEINA CO.,LTD.
A biotech firm analyzing protein interactions for drug and …
|
468530 | KR | Professional, scientific and te… |
BRIM via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52650/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52650 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52650 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52650 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52650}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BRIM (id: 52650)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.